13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Reduced Vglut2/Slc17a6 Gene Expression Levels throughout the Mouse Subthalamic Nucleus Cause Cell Loss and Structural Disorganization Followed by Increased Motor Activity and Decreased Sugar Consumption

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Visual Abstract

          Abstract

          The subthalamic nucleus (STN) plays a central role in motor, cognitive, and affective behavior. Deep brain stimulation (DBS) of the STN is the most common surgical intervention for advanced Parkinson’s disease (PD), and STN has lately gained attention as target for DBS in neuropsychiatric disorders, including obsessive compulsive disorder, eating disorders, and addiction. Animal studies using STN-DBS, lesioning, or inactivation of STN neurons have been used extensively alongside clinical studies to unravel the structural organization, circuitry, and function of the STN. Recent studies in rodent STN models have exposed different roles for STN neurons in reward-related functions. We have previously shown that the majority of STN neurons express the vesicular glutamate transporter 2 gene ( Vglut2/Slc17a6) and that reduction of Vglut2 mRNA levels within the STN of mice [conditional knockout (cKO)] causes reduced postsynaptic activity and behavioral hyperlocomotion. The cKO mice showed less interest in fatty rewards, which motivated analysis of reward-response. The current results demonstrate decreased sugar consumption and strong rearing behavior, whereas biochemical analyses show altered dopaminergic and peptidergic activity in the striatum. The behavioral alterations were in fact correlated with opposite effects in the dorsal versus the ventral striatum. Significant cell loss and disorganization of the STN structure was identified, which likely accounts for the observed alterations. Rare genetic variants of the human VGLUT2 gene exist, and this study shows that reduced Vglut2/Slc17a6 gene expression levels exclusively within the STN of mice is sufficient to cause strong modifications in both the STN and the mesostriatal dopamine system.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Imaging dopamine's role in drug abuse and addiction.

          Dopamine is involved in drug reinforcement but its role in addiction is less clear. Here we describe PET imaging studies that investigate dopamine's involvement in drug abuse in the human brain. In humans the reinforcing effects of drugs are associated with large and fast increases in extracellular dopamine, which mimic those induced by physiological dopamine cell firing but are more intense and protracted. Since dopamine cells fire in response to salient stimuli, supraphysiological activation by drugs is experienced as highly salient (driving attention, arousal, conditioned learning and motivation) and with repeated drug use may raise the thresholds required for dopamine cell activation and signaling. Indeed, imaging studies show that drug abusers have marked decreases in dopamine D2 receptors and in dopamine release. This decrease in dopamine function is associated with reduced regional activity in orbitofrontal cortex (involved in salience attribution; its disruption results in compulsive behaviors), cingulate gyrus (involved in inhibitory control; its disruption results in impulsivity) and dorsolateral prefrontal cortex (involved in executive function; its disruption results in impaired regulation of intentional actions). In parallel, conditioning triggered by drugs leads to enhanced dopamine signaling when exposed to conditioned cues, which then drives the motivation to procure the drug in part by activation of prefrontal and striatal regions. These findings implicate deficits in dopamine activity-inked with prefrontal and striatal deregulation-in the loss of control and compulsive drug intake that results when the addicted person takes the drugs or is exposed to conditioned cues. The decreased dopamine function in addicted individuals also reduces their sensitivity to natural reinforcers. Therapeutic interventions aimed at restoring brain dopaminergic tone and activity of cortical projection regions could improve prefrontal function, enhance inhibitory control and interfere with impulsivity and compulsive drug administration while helping to motivate the addicted person to engage in non-drug related behaviors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Brain dopamine and obesity.

            The cerebral mechanisms underlying the behaviours that lead to pathological overeating and obesity are poorly understood. Dopamine, a neurotransmitter that modulates rewarding properties of food, is likely to be involved. To test the hypothesis that obese individuals have abnormalities in brain dopamine activity we measured the availability of dopamine D2 receptors in brain. Brain dopamine D2 receptor availability was measured with positron emission tomography (PET) and [C-11]raclopride (a radioligand for the dopamine D2 receptor). Bmax/Kd (ratio of the distribution volumes in striatum to that in cerebellum minus 1) was used as a measure of dopamine D2 receptor availability. Brain glucose metabolism was also assessed with 2-deoxy-2[18F]fluoro-D-glucose (FDG). Striatal dopamine D2 receptor availability was significantly lower in the ten obese individuals (2.47 [SD 0.36]) than in controls (2.99 [0.41]; p < or = 0.0075). In the obese individuals body mass index (BMI) correlated negatively with the measures of D2 receptors (r=0.84; p < or = 0.002); the individuals with the lowest D2 values had the largest BMI. By contrast, neither whole brain nor striatal metabolism differed between obese individuals and controls, indicating that striatal reductions in D2 receptors were not due to a systematic reduction in radiotracer delivery. The availability of dopamine D2 receptor was decreased in obese individuals in proportion to their BMI. Dopamine modulates motivation and reward circuits and hence dopamine deficiency in obese individuals may perpetuate pathological eating as a means to compensate for decreased activation of these circuits. Strategies aimed at improving dopamine function may be beneficial in the treatment of obese individuals.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Behavioural assessment of drug reinforcement and addictive features in rodents: an overview.

              Some psychoactive drugs are abused because of their ability to act as reinforcers. As a consequence behavioural patterns (such as drug-seeking/drug-taking behaviours) are promoted that ensure further drug consumption. After prolonged drug self-administration, some individuals lose control over their behaviour so that these drug-seeking/taking behaviours become compulsive, pervading almost all life activities and precipitating the loss of social compatibility. Thus, the syndrome of addictive behaviour is qualitatively different from controlled drug consumption. Drug-induced reinforcement can be assessed directly in laboratory animals by either operant or non-operant self-administration methods, by classical conditioning-based paradigms such as conditioned place preference or sign tracking, by facilitation of intracranial electric self-stimulation, or, alternatively by drug-induced memory enhancement. In contrast, addiction cannot be modelled in animals, at least as a whole, within the constraints of the laboratory. However, various procedures have been proposed as possible rodent analogues of addiction's major elements including compulsive drug seeking, relapse, loss of control/impulsivity, and continued drug consumption despite negative consequences. This review provides an extensive overview and a critical evaluation of the methods currently used for studying drug-induced reinforcement as well as specific features of addictive behaviour. In addition, comic strips that illustrate behavioural methods used in the drug abuse field are provided given for free download under http://www.zi-mannheim/psychopharmacology.de.
                Bookmark

                Author and article information

                Journal
                eNeuro
                eNeuro
                eneuro
                eneuro
                eNeuro
                eNeuro
                Society for Neuroscience
                2373-2822
                15 September 2016
                29 September 2016
                Sep-Oct 2016
                : 3
                : 5
                : ENEURO.0264-16.2016
                Affiliations
                [1 ]Department of Organismal Biology, Uppsala University , SE-752 36 Uppsala, Sweden
                [2 ]Department of Neuroscience, Uppsala University , SE-751 24 Uppsala, Sweden
                [3 ]Faculty of Pharmacy, Université de Montréal , Montréal, QC H3T 1J4, Canada
                [4 ]Oramacell , 75006 Paris, France
                [5 ]Department of Pharmaceutical Biosciences, Uppsala University , SE-751 24 Uppsala, Sweden
                [6 ]Department of Chemistry, BMC - Analytical Chemistry and Neurochemistry, Uppsala University , SE-751 24 Uppsala, Sweden
                Author notes

                The authors declare no competing interests.

                Author contributions: N.S., T.V., C.J.A.S.-A., D.L., Å.K.-G., M.A., S.D., and Å.W.-M. designed research; N.S., T.V., C.J.A.S.-A., K.N., E.A., S.M., A.Z., H.W.J., J.B., D.L., M.A., S.D., and Å.W.-M. performed research; N.S., T.V., C.J.A.S.-A., A.Z., J.B., D.L., Å.K.-G., M.A., S.D., and Å.W.-M. analyzed data; N.S., T.V., C.J.A.S.-A., Å.K.-G., and Å.W.-M. wrote the paper.

                This work was supported by grants from the Swedish Research Council (Vetenskapsrådet 2013-4657, 2014-3804, 2011-4423, 2015-4870, and 2012-2304), Uppsala University, The Swedish Brain Foundation, Parkinsonfonden, Hållsten Research Foundation, and the research foundations of Gösta Lind, Åhlén, and Åke Wiberg.

                [*]

                N.S. and T.V. contributed equally to this work.

                Sylvie Dumas is the owner of Oramacell, Paris, France.

                C.J.A. Smith-Anttila’s present address: Department of Anatomy and Neurosciences, The University of Melbourne, Victoria 3010, Australia; E. Arvidsson’s present address: Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden; N. Schweizer’s and K. Nordenankar’s present address: Department of Pharmaceutical Biosciences, Uppsala University, SE-751 24 Uppsala, Sweden.

                Correspondence should be addressed to Åsa Wallén-Mackenzie, Uppsala University, Department of Organismal Biology/Comparative Physiology, Norbyvägen 18A, SE-752 36 Uppsala, Sweden. E-mail: asa.mackenzie@ 123456ebc.uu.se .
                Author information
                http://orcid.org/0000-0002-8701-2690
                http://orcid.org/0000-0001-9039-7707
                http://orcid.org/0000-0002-8739-9645
                http://orcid.org/0000-0002-8713-070X
                Article
                eN-NWR-0264-16
                10.1523/ENEURO.0264-16.2016
                5041164
                27699212
                7fff6f8f-b7c7-406d-9bdf-e9c789e5f1bf
                Copyright © 2016 Schweizer et al.

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

                History
                : 2 September 2016
                : 8 September 2016
                Page count
                Figures: 9, Tables: 0, Equations: 0, References: 81, Pages: 19, Words: 13139
                Funding
                Funded by: Swedish research council
                Award ID: 2013-4657
                Award ID: 2014-3804
                Award ID: 2011-4423
                Award ID: 2015-4870
                Award ID: 2012-2304
                Funded by: The brain foundation
                Funded by: Bertil Hållsten Research Foundation
                Funded by: Foundation of Gösta Lind
                Funded by: Foundation of Åhlén
                Funded by: Foundation of Åke Wiberg
                Categories
                1
                New Research
                Cognition and Behavior
                Custom metadata
                September/October 2016

                dopamine,dynorphin,glutamate,rearing,reward,self-administration
                dopamine, dynorphin, glutamate, rearing, reward, self-administration

                Comments

                Comment on this article